Frontage (HKG:1521) recorded a net loss of around $900,000 in the first quarter of 2025, narrower than $1 million a year prior, a Monday Hong Kong bourse filing said.
Revenue for the biotech firm fell 11% year over year to $57.1 million in the three months from $63.9 million in the year-ago period.